Herbs (Global Traditional) · Amazonian
Tabebuia impetiginosa
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Tabebuia impetiginosa is an Amazonian tree bark containing lapachol and β-lapachone as primary bioactive compounds. These naphthoquinones demonstrate anti-inflammatory activity by suppressing pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β.
Tabebuia impetiginosa, also known as Pau d'Arco or Handroanthus impetiginosus, is a deciduous tree native to tropical South America, including Brazil, Argentina, and Bolivia. The primary therapeutic source is the inner bark, which is extracted using methods such as water infusion, methanol, ethyl acetate, or other solvents to obtain naphthoquinone-rich extracts.
Clinical evidence for Tabebuia impetiginosa is extremely limited, with most research confined to in vitro and animal studies. The only human study identified used a related species (T. avellanedae) at 1050 mg/day for 8 weeks in 20 women with dysmenorrhea, showing tolerability but no efficacy data (PMC10032363). Isolated compounds like β-lapachone have reached phase 2 cancer trials, but these do not represent whole-plant extract studies.
Human clinical data is limited to a related species (T. avellanedae) at 1050 mg/day powder for 8 weeks. Animal studies used 100-400 mg/kg orally of aqueous or ethanol extracts. No standardization protocols have been established for lapachol or β-lapachone content. Consult a healthcare provider before starting any new supplement.
Tabebuia impetiginosa (Pau d'Arco) bark is not a significant source of conventional macronutrients or micronutrients in typical supplemental doses; its nutritional relevance lies almost entirely in its bioactive phytochemical content. Primary bioactive compounds include naphthoquinones, most notably lapachol (concentrations of 2–7% dry weight in inner bark, varying by region and extraction method) and beta-lapachone (present in smaller quantities, typically <1% dry weight). Additional naphthoquinones identified include dehydro-alpha-lapachone and xyloidone. The bark also contains furanonaphthoquinones, anthraquinones (including tabebuin), and iridoids. Flavonoids are present including quercetin and kaempferol derivatives, contributing secondary antioxidant activity. Tannins and catechins are present at moderate levels (~3–8% dry weight), contributing astringency and additional antioxidant capacity. Coumarin derivatives have been detected in small quantities. Mineral content in the bark is minimal; trace amounts of calcium, magnesium, and potassium are detectable but not nutritionally meaningful at standard supplement doses (typically 500–1000 mg bark extract). Fiber is present structurally in the bark matrix but not bioavailable in extract or tea form. Protein content is negligible (<1% in extracted forms). Bioavailability note: lapachol exhibits moderate oral bioavailability in animal models but undergoes significant first-pass metabolism; beta-lapachone has poor aqueous solubility, limiting absorption without formulation aids such as cyclodextrin complexes or lipid-based delivery systems. Aqueous tea preparations (decoctions) extract primarily water-soluble flavonoids and tannins, while ethanolic or standardized extracts yield higher naphthoquinone concentrations.
The naphthoquinones lapachol and β-lapachone in Tabebuia impetiginosa inhibit nuclear factor-κB (NF-κB) signaling pathways. This suppression reduces production of pro-inflammatory cytokines TNF-α, IL-6, IL-1β, and IL-8 in human peripheral blood mononuclear cells. The compounds also modulate cyclooxygenase and lipoxygenase pathways involved in inflammatory mediator synthesis.
Current evidence for Tabebuia impetiginosa consists primarily of preliminary animal and in vitro studies. Animal models showed anti-inflammatory effects at 100-400 mg/kg doses, reducing carrageenan-induced paw edema. In vitro studies using human PBMCs demonstrated cytokine suppression at concentrations of 32-100 µg/mL. No human clinical trials have been conducted to establish therapeutic efficacy or optimal dosing protocols.
Safety data for Tabebuia impetiginosa supplementation is limited due to lack of human clinical trials. The naphthoquinone compounds may interact with anticoagulant medications due to potential effects on blood clotting. Pregnancy and breastfeeding safety has not been established. High doses may cause gastrointestinal upset based on traditional use reports, though specific adverse effects remain undocumented in controlled studies.
